Ovum, an Australian women’s health company founded by Ariella Heffernan-Marks, has raised $4 million in seed funding to address the gender health gap, tripling its valuation just one year after securing $1.7 million in a pre-seed round.

In a statement on Tuesday, Ovum said the round was led by Admiralty Capital Group. It had the participation from Antler, Giant Leap, Aviron Investments, Foggy Valley Aotearoa, Brisbane Angels, and Think & Grow, alongside an increased investment from LaunchVic through The Alice Anderson Fund.

Ovum is building AI infrastructure for women’s health that captures symptoms, lifestyle, biometrics, reproductive health stages, medications, appointments, and medical reports into a single longitudinal memory. It can generate health summaries and appointment-ready questions to help women advocate for themselves in clinical settings.

Since launching in August 2025, Ovum has grown 30 percent month-on-month, with more than 20,000 downloads, 60,000 women’s health data insights captured, and more than 113,000 AI health conversations from women aged 15 to 84.

Amanda Andriano, Founding Partner of Admiralty Capital Group, said Ovum combines mission, market timing, and technical capability with an exceptional founder, creating the foundation for a company of global significance.

Heffernan-Marks said the funding allows the company to scale its mission responsibly while building a platform grounded in clinical integrity, privacy, and consent.

Ovum said 83 percent of its users have opted in to share anonymised data for research purposes, with data handled to global standards including GDPR and SOC 2 Type II. Earlier this year, Ovum launched clinical trials with St George Hospital and the Royal Hospital for Women to assess AI as a preventative health tool for women.

Google, Telstra to jointly strengthen Australia’s digital, subsea connectivity